Maze Therapeutics' CMO Sells Entire Direct Stock Stake for $255K
Harold Bernstein, Chief Medical Officer at Maze Therapeutics (NASDAQ:MAZE), sold all of his directly held shares in the company on September 4, 2026. The transaction involved 9,705 shares and was executed under a Rule 10b5-1 trading plan for $26.22 per share, totaling approximately $255,000. This sale marks Bernstein's complete exit from direct ownership in the company’s stock but does not reflect his broader holdings through derivative securities like options and restricted shares. The transaction comes amid a challenging period for Maze Therapeutics' stock price, which has fallen nearly 50% since its March 2026 peak of $53.65 to close at around $24.82 as of September 10. The company is in the clinical stage and focuses on developing precision medicines targeting kidney and metabolic diseases. Its lead programs include MZE829 for APOL1 kidney disease and MZE782 for phenylketonuria, both at advanced stages of development.
Tickers: $MAZE
Topics: Harold Bernstein Maze Therapeutics Rule 10b5-1 trading plan SEC Form 4 filing